---
schema_version: "secwatch.filing_event.v1"
accession: "0001854270-25-000038"
form_type: "8-K"
ticker: "SNTI"
cik: "0001854270"
company_name: "Senti Biosciences, Inc."
filed_at: "2025-03-20T23:59:59+00:00"
generated_at: "2026-05-24T10:48:24.473135+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Senti Bio reports Q4 net loss $0.6M; two AML patients remain in remission from SENTI-202 trial

## Summary
- Q4 net loss $0.6M ($0.67/share); full year net loss $52.8M ($12.03/share).
- SENTI-202 Phase 1: 2 of 3 AML patients achieved MRD-negative CR; both still in remission as of March 2025.
- Raised $47.6M gross from PIPE in Dec 2024; net $45.1M extends cash runway into 2026.
- Cash $48.3M at Dec 31, 2024; received additional $1.5M from CIRM grant in Jan 2025.
- Appointed Jay Cross CFO and Faraz Siddiqui SVP Tech Ops in Feb 2025; added two board members.

## SEC filing metadata
- accession: 0001854270-25-000038
- form_type: 8-K
- ticker: SNTI
- cik: 0001854270
- company_name: Senti Biosciences, Inc.
- filed_at: 2025-03-20T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1854270/000185427025000038/0001854270-25-000038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1854270/000185427025000038/snti-20250320.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001854270-25-000038
- JSON: https://secwatch.observer/filing/0001854270-25-000038.json
- Plain text: https://secwatch.observer/filing/0001854270-25-000038.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.